SIKA Stock Analysis: Sika | SW
Specialty Chemicals | SW, Switzerland | Market Cap: 25.004m CHF | 12M Return: -20.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 65.0M
Qual. Beats: 0
Rev. Trend: 82.6%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Sika AG is a Swiss specialty chemicals company founded in 1910 and headquartered in Baar, Switzerland. It develops and sells systems and products for bonding, sealing, damping, reinforcing, and protecting applications, serving two principal end markets: the global building sector and the motor vehicle industry.
The companys product portfolio spans concrete admixtures and additives, waterproofing systems (sold under the SikaProof brand), flat roofing membranes (Sika Sarnafil), tile adhesives and grouts, industrial and commercial flooring resins, and a range of sealants, spray foams, and tapes. It markets these primarily to commercial, residential, and infrastructure construction customers, as well as to automobile and commercial vehicle assembly, industrial lamination, renewable energy, home appliances, and advanced resins manufacturers.
As a specialty chemicals producer, Sika competes on formulation expertise and technical service rather than commodity-scale production. Its products are largely specification-driven, meaning engineers, architects, and OEMs select Sika systems during the design phase of construction or manufacturing projects. The business model is predominantly B2B, with sales routed through distributors, contractors, and direct accounts, and demand is closely tied to global construction activity, infrastructure spending, and automotive production volumes.
- Global construction recovery lifts admixtures and roofing sales
- Raw material cost inflation squeezes specialty chemicals margins
- MBCC integration expands construction chemicals market share
| Net Income: 2.03b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -0.56 > 1.0 |
| NWC/Revenue: 4.41% < 20% (prev 11.04%; Δ -6.63% < -1%) |
| CFO/TA 0.10 > 3% & CFO 1.59b > Net Income 2.03b |
| Net Debt (5.15b) to EBITDA (3.39b): 1.52 < 3 |
| Current Ratio: 1.25 > 1.5 & < 3 |
| Outstanding Shares: last quarter (160.5m) vs 12m ago 0.13% < -2% |
| Gross Margin: 47.96% > 18% (prev 39.44%; Δ 8.52% > 0.5%) |
| Asset Turnover: 127.8% > 50% (prev 112.1%; Δ 15.72% > 0%) |
| Interest Coverage Ratio: 18.04 > 6 (EBIT TTM 2.85b / Interest Expense TTM 157.9m) |
| A: 0.06 (Total Current Assets 4.41b - Total Current Liabilities 3.53b) / Total Assets 15.4b |
| B: 0.44 (Retained Earnings 6.74b / Total Assets 15.4b) |
| C: 0.18 (EBIT TTM 2.85b / Avg Total Assets 15.7b) |
| D: 0.77 (Book Value of Equity 6.66b / Total Liabilities 8.70b) |
| Altman-Z'' = 3.83 = AA |
| DSRI: 0.80 (Receivables 2.20b/2.47b, Revenue 20.0b/17.9b) |
| GMI: 0.82 (GM 39.44% / 47.96%) |
| AQI: 0.99 (AQ_t 0.55 / AQ_t-1 0.56) |
| SGI: 1.12 (Revenue 20.0b / 17.9b) |
| TATA: 0.03 (NI 2.03b - CFO 1.59b) / TA 15.4b) |
| Beneish M = -3.27 (Cap -4..+1) = AA |
As of July 29, 2026, the stock is trading at CHF 161.25 with a total of 458,881 shares traded. Over the past week, the price has changed by +3.76%, over one month by -1.32%, over three months by +10.94% and over the past year by -20.81%.
Current recommended Stop Loss: 156.20 (which is 3.1% or 1.2 ATR below the current price).
Sika has no consensus analysts rating.
P/E Trailing = 23.9769
P/E Forward = 21.4133
P/S = 2.2323
P/B = 3.7565
P/EG = 2.4327
Revenue TTM = 20.0b CHF
EBIT TTM = 2.85b CHF
EBITDA TTM = 3.39b CHF
Long Term Debt = 3.80b CHF (from longTermDebt, last quarter)
Short Term Debt = 1.39b CHF (from shortTermDebt, last quarter)
Debt = 5.96b CHF (from shortLongTermDebtTotal, last quarter) + Leases 438.2m
Net Debt = 5.15b CHF (calculated: Debt 5.96b - CCE 801.8m)
Enterprise Value = 30.2b CHF (25.0b + Debt 5.96b - CCE 801.8m)
Interest Coverage Ratio = 18.04 (Ebit TTM 2.85b / Interest Expense TTM 157.9m)
EV/FCF = 24.22x (Enterprise Value 30.2b / FCF TTM 1.25b)
FCF Yield = 4.13% (FCF TTM 1.25b / Enterprise Value 30.2b)
FCF Margin = 6.22% (FCF TTM 1.25b / Revenue TTM 20.0b)
Net Margin = 10.14% (Net Income TTM 2.03b / Revenue TTM 20.0b)
Gross Margin = 47.96% ((Revenue TTM 20.0b - Cost of Revenue TTM 10.4b) / Revenue TTM)
Gross Margin QoQ = 54.74% (prev 54.64%)
Tobins Q-Ratio = 1.96 (Enterprise Value 30.2b / Total Assets 15.4b)
Interest Expense / Debt = 2.65% (Interest Expense 157.9m / Debt 5.96b)
Taxrate = 21.21% (546.1m / 2.57b)
NOPAT = 2.24b (EBIT 2.85b * (1 - 21.21%))
Current Ratio = 1.25 (Total Current Assets 4.41b / Total Current Liabilities 3.53b)
Debt / Equity = 0.89 (Debt 5.96b / totalStockholderEquity, last quarter 6.66b)
Debt / EBITDA = 1.52 (Net Debt 5.15b / EBITDA 3.39b)
Debt / FCF = 4.14 (Net Debt 5.15b / FCF TTM 1.25b)
Total Stockholder Equity = 6.57b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.96% (Net Income 2.03b / Total Assets 15.4b)
RoE = 30.91% (Net Income TTM 2.03b / Total Stockholder Equity 6.57b)
RoCE = 27.45% (EBIT 2.85b / Capital Employed (Equity 6.57b + L.T.Debt 3.80b))
RoIC = 18.06% (NOPAT 2.24b / Invested Capital 12.4b)
WACC = 7.37% (E(25.0b)/V(31.0b) * Re(8.63%) + D(5.96b)/V(31.0b) * Rd(2.65%) * (1-Tc(0.21)))
Discount Rate = 8.63% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 21.51 | Cagr: 0.35%
[DCF] Terminal Value 73.96% ; FCFF base≈1.30b ; Y1≈1.20b ; Y5≈1.06b
[DCF] Fair Price = 72.93 (EV 16.9b - Net Debt 5.15b = Equity 11.7b / Shares 160.4m; r=8.35% [WACC [floored]]; 5y FCF grow -10.02% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 82.56 | Revenue CAGR: 11.25% | SUE: -0.00 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=7.40 | Chg30d=+0.56% | Revisions=+44% | GrowthEPS=+11.4% | GrowthRev=-0.2%
EPS next Year (2027-12-31): EPS=8.09 | Chg30d=+0.36% | Revisions=+58% | GrowthEPS=+12.4% | GrowthRev=+5.6%
[Analyst] Revisions Ratio: +61% (up=13, down=2)